Xuanzhu Biopharmaceutical: Out Licensing Agreement A Positive, But Not Enough for a Sustainable Play
​Xuanzhu Biopharmaceutical signs licensing deal with Boston Oncology for Bireociclib and Dirozalkib. Revenue up 72% in 2025, but challenges ahead...
160 Views
APAC Healthcare Weekly (Sept 6) – Simcere, Hutchmed, Akeso, Daiichi Sankyo, Alteogen, Pharmaessentia
Simcere and Hutchmend inked outlicensing deals with Roche and GSK, respectively. Akeso’s ivonescimab extends lives vs Keytruda. Alteogen inked...
103 Views
Primer: Xuanzhu Biopharmaceutical (XUANZHU HK) - Nov 2025
Xuanzhu Biopharmaceutical is a clinical-stage biopharmaceutical company spun off from its controlling shareholder, Sihuan Pharmaceutical, with...
152 Views
APAC Healthcare Weekly (June 28) – Insilico, Abbisko, Nippon Shinyaku, Otsuka, Yuhan Corp, Medytox
Few Chinese companies signed outlicensing deals. Nippon Shinyaku’s partner Regenxbio will resubmit gene therapy drug candidate to FDA. Otsuka...
144 Views
APAC Healthcare Weekly (April 19) – Fosun Pharma, Remegen, Daiichi Sankyo, Astellas Pharma, Telix
FDA granted Priority Review to Daiichi Sankyo’s I-DXd. Astellas Pharma initiates Phase 3 study for setidegrasib. Telix and Regeneron...
467 Views